Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med.
André F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol.
2012;23 (Suppl 6):vi46-vi51. 3.
Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst.
2015;107(6): djv048. 4.
Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chapar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine (Baltimore).
Breast Cancer Hormone Receptor Status. American Cancer Society website. https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-hormone-receptor-status.html
. Accessed November 30, 2020. 6.
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Sub-typing of triple-negative breast cancer: implications for therapy. Cancer.
Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009; 20(7):1071-1082.